Details of the Drug Combinations

General Information of This Drug (ID: DMAGFOD)

Drug Name
Semaglutide   DMAGFOD
Synonyms NN9535
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Omeprazole + Semaglutide DCZCFTW Omeprazole Diabetes [2]
Semaglutide + Probenecid DCJEIB5 Probenecid Diabetes [3]
Semaglutide + Semaglutide DCPWALV Semaglutide Diabetes Mellitus, Type 2 [4]
Semaglutide + Atorvastatin DCTNXZH Atorvastatin Diabetes [5]
Levonorgestrel + Semaglutide DCBLT01 Levonorgestrel Endometrial Cancer [6]
Semaglutide + Dapagliflozin DCQZIFJ Dapagliflozin Kidney Transplant Recipients [7]
Semaglutide + GTx-024 DCYV615 GTx-024 Muscle Loss [8]
Semaglutide + Empagliflozin DCITDAS Empagliflozin Type 2 Diabetes With Renal Manifestations [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 ClinicalTrials.gov (NCT02249871) Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
3 ClinicalTrials.gov (NCT03466567) A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
4 ClinicalTrials.gov (NCT03611322) A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)
5 ClinicalTrials.gov (NCT02243098) Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
6 ClinicalTrials.gov (NCT06073184) Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
7 ClinicalTrials.gov (NCT05938712) The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
8 ClinicalTrials.gov (NCT06282458) Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
9 ClinicalTrials.gov (NCT04061200) Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria